De Chao Yu
Chief Executive Officer chez INNOVENT BIOLOGICS, INC.
Fortune : 638 M $ au 29/02/2024
Profil
Fondateur d'Innovent Biologics, Inc. et de Chengdu Kanghong Pharmaceutical Group Co., Ltd, De Chao Yu occupe le poste de président-directeur général d'Innovent Biologics, Inc. et de président de la Chinese Antibody Society. Il est également membre du conseil d'administration du Babytree Group et du Cheerwin Group Ltd. et professeur à l'université du Sichuan. De Chao Yu était auparavant président et directeur général de Chengdu Kanghong Pharmaceutical Group Co. Ltd, vice-président de la recherche et du développement d'Applied Genetic Technologies Corp, vice-président de la recherche et du développement d'Applied Genetics, Inc, président et directeur général de Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd, vice-président chargé de la recherche et du développement chez Calyon North America, Inc. et vice-président chez Calydon, Inc. et directeur général de la China Medicinal Biotech Association. Il a reçu un doctorat de l'Académie chinoise des sciences.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
INNOVENT BIOLOGICS, INC.
7,27% | 17/10/2023 | 117 903 209 ( 7,27% ) | 638 M $ | 29/02/2024 |
Postes actifs de De Chao Yu
Sociétés | Poste | Début |
---|---|---|
INNOVENT BIOLOGICS, INC. | Chief Executive Officer | 28/04/2011 |
Sichuan University | Corporate Officer/Principal | 01/01/2008 |
Chinese Antibody Society | Chairman | 01/01/2017 |
Anciens postes connus de De Chao Yu
Sociétés | Poste | Fin |
---|---|---|
BABYTREE GROUP | Director/Board Member | 10/05/2023 |
CHEERWIN GROUP LIMITED | Director/Board Member | 14/10/2022 |
China Medicinal Biotech Association | Corporate Officer/Principal | 01/01/2019 |
PHARMABLOCK SCIENCES (NANJING), INC. | Director/Board Member | 01/01/2018 |
CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Chief Executive Officer | 01/01/2011 |
Formation de De Chao Yu
Chinese Academy of Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Health Technology |
INNOVENT BIOLOGICS, INC. | Health Technology |
PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
BABYTREE GROUP | Commercial Services |
CHEERWIN GROUP LIMITED | Process Industries |
Entreprise privées | 7 |
---|---|
Calydon, Inc.
Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The private company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Beacon Therapeutics (USA), Inc.
Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Calyon North America, Inc.
Calyon North America, Inc. Regional BanksFinance Part of SAS Rue la Boétie, Calyon North America, Inc. is a private company based in New York, NY. | Finance |
China Medicinal Biotech Association | |
Applied Genetics, Inc. | |
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd.
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ellimist Singapore Pte Ltd., Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. is a pharmaceutical company that manufactures and supplies pharmaceutical products. The private company is based in Chengdu, China. Kanghong Sagent Chengdu Pharmaceutical Corp. was acquired by Sagent Pharmaceuticals, Inc., part of Ellimist Singapore Pte Ltd. from February 28, 2023 on June 04, 2013 for $4.06 million. The Chinese company was founded in 2006. | Health Technology |
Chinese Antibody Society |